Treatment A: Doravirine 100 mg film coated tablet + Treatment B: Doravirine 150 mg tablet (40% drug loaded granule) + Treatment C: Doravirine 150 mg tablet (30% drug loaded granule) + Treatment D: Doravirine 150 mg tablet (50% drug loaded granule) + Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)
Phase 1CompletedDevelopment Stage
Human Immunodeficiency Virus-1 (HIV-1)
Human Immunodeficiency Virus-1 (HIV-1)
Sep 21, 2015 → Dec 24, 2015
About Treatment A: Doravirine 100 mg film coated tablet + Treatment B: Doravirine 150 mg tablet (40% drug loaded granule) + Treatment C: Doravirine 150 mg tablet (30% drug loaded granule) + Treatment D: Doravirine 150 mg tablet (50% drug loaded granule) + Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)
Treatment A: Doravirine 100 mg film coated tablet + Treatment B: Doravirine 150 mg tablet (40% drug loaded granule) + Treatment C: Doravirine 150 mg tablet (30% drug loaded granule) + Treatment D: Doravirine 150 mg tablet (50% drug loaded granule) + Treatment E: Doravirine 100 mg tablet (30% drug loaded granule) is a phase 1 stage product being developed by Merck for Human Immunodeficiency Virus-1 (HIV-1). The current trial status is completed. This product is registered under clinical trial identifier NCT02549040. Target conditions include Human Immunodeficiency Virus-1 (HIV-1).
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02549040 | Phase 1 | Completed |
Competing Products
20 competing products in Human Immunodeficiency Virus-1 (HIV-1)